PLSE icon

Pulse Biosciences

16.64 USD
+0.90
5.72%
At close Updated Sep 16, 4:00 PM EDT
Pre-market
After hours
16.64
0.00
0%
1 day
5.72%
5 days
11.98%
1 month
6.12%
3 months
8.55%
6 months
3.68%
Year to date
-6.46%
1 year
-18.39%
5 years
36.51%
10 years
299.04%
 

About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

Employees: 75

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

19% more call options, than puts

Call options by funds: $653K | Put options by funds: $550K

4% more funds holding

Funds holding: 83 [Q1] → 86 (+3) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 29

0.34% less ownership

Funds ownership: 9.23% [Q1] → 8.89% (-0.34%) [Q2]

1% less capital invested

Capital invested by funds: $91.4M [Q1] → $90.3M (-$1.08M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$22
32% upside
Avg. target
$22
32% upside
High target
$22
32% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Oppenheimer
Suraj Kalia
$22
Outperform
Initiated
7 Jul 2025

Financial journalist opinion

Based on 7 articles about PLSE published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
Neutral
Business Wire
6 days ago
Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the company will present clinical data on benign thyroid nodule ablation using nPulse™ Vybrance™ technology at the American Thyroid Association Annual Meeting from September 10-14th in Scottsdale, AZ. “We believe the differentiated nPulse Vybrance Percutaneous El.
Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
Neutral
Business Wire
8 days ago
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company's Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the.
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
Neutral
Business Wire
12 days ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and i.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
14 days ago
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences' nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules (BTNs). “Successful procedures for the first enrolled patients in our PRECISE-BTN clinical study for the treatment.
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
Positive
Zacks Investment Research
20 days ago
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Neutral
Business Wire
21 days ago
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced a new publication in the Journal Thyroid. The First-in-Human Clinical feasibility study demonstrates the effectiveness of ablation of benign thyroid nodules using nsPFA energy. The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the trea.
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
Neutral
Seeking Alpha
1 month ago
Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jon Skinner - Chief Financial Officer Paul Arthur LaViolette - President, CEO, Principal Executive Officer, Principal Financial Officer & Co- Chairman of the Board Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Joshua Thomas Jennings - TD Cowen, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Philip Taylor - Gilmartin Group LLC Operator Thank you for standing by. Hello, and welcome to the Pulse Biosciences Second Quarter 2025 Earnings Conference Call.
Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multi.
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Pr.
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
Charts implemented using Lightweight Charts™